Abstract

Further evidence of the limitations of Activated Partial Thromboplastin Time to monitor Argatroban

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Laboratory methods for monitoring argatroban in heparin-induced thrombocytopenia.
Susan Guy ... Steve Kitchen
International journal of laboratory hematology | VOL. 44
Susan Guy, et. al.Susan Guy ... Steve Kitchen
09 Nov 2021
Caution in Using the Activated Partial Thromboplastin Time to Monitor Argatroban in COVID-19 and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT).
Michael Makris ... Rhona M Maclean
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis | VOL. 27
Michael Makris, et. al.Michael Makris ... Rhona M Maclean
01 Jan 2020
Effect of warfarin on the activated partial thromboplastin time.
Valerie M Hauser ... Susan L Rozek
Drug intelligence & clinical pharmacy | VOL. 20
Valerie M Hauser, et. al.Valerie M Hauser ... Susan L Rozek
01 Dec 1986
The multiple faces of the partial thromboplastin time APTT
J Hirsh ... S Bates
Journal of Thrombosis and Haemostasis | VOL. 2
J Hirsh, et. al.J Hirsh ... S Bates
01 Dec 2004
View more papers

More From: British Journal of Haematology

Paper Title
Journal
Date
Author
Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T-cell therapy in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Tamer Othman ... Ibrahim Aldoss
British journal of haematology | VOL. -
Tamer Othman, et. al.Tamer Othman ... Ibrahim Aldoss
29 May 2024
Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I-BFM Study Group.
Herbert Pichler ... Adriana Balduzzi
British journal of haematology | VOL. -
Herbert Pichler, et. al.Herbert Pichler ... Adriana Balduzzi
27 May 2024
Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP.
Douglas A Stewart ... Michael Crump
British journal of haematology | VOL. -
Douglas A Stewart, et. al.Douglas A Stewart ... Michael Crump
27 May 2024
RUNX1::ETO and CBFβ::MYH11 converge on aberrant activation of BCAT1 to confer a therapeutic vulnerability in core-binding factor-acute myeloid leukaemia.
Siyang Wang ... Kankan Wang
British journal of haematology | VOL. -
Siyang Wang, et. al.Siyang Wang ... Kankan Wang
27 May 2024
View more papers